RHJA
BMRN icon

Rice Hall James & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rice Hall James & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.91M Buy
104,659
+4,489
+4% +$262K 0.33% 73
2025
Q4 		$5.95M Sell
100,170
-3,255
-3% -$177K 0.33% 73
2025
Q3 		$5.6M Buy
103,425
+97,657
+1,693% +$5.58M 0.31% 79
2025
Q2 		$317K Sell
5,768
-112
-2% -$6.59K 0.02% 238
2025
Q1 		$416K Buy
5,880
+89
+2% +$5.99K 0.02% 230
2024
Q4 		$381K Sell
5,791
-4,536
-44% -$304K 0.02% 238
2024
Q3 		$726K Sell
10,327
-10,352
-50% -$865K 0.04% 214
2024
Q2 		$1.7M Sell
20,679
-8,043
-28% -$670K 0.1% 174
2024
Q1 		$2.51M Sell
28,722
-692
-2% -$61.9K 0.14% 149
2023
Q4 		$2.84M Sell
29,414
-1,453
-5% -$129K 0.16% 134
2023
Q3 		$2.73M Sell
30,867
-1,818
-6% -$162K 0.17% 133
2023
Q2 		$2.83M Sell
32,685
-1,354
-4% -$127K 0.16% 143
2023
Q1 		$3.31M Sell
34,039
-369
-1% -$38.3K 0.19% 132
2022
Q4 		$3.56M Buy
34,408
+13,377
+64% +$1.26M 0.2% 119
2022
Q3 		$1.78M Sell
21,031
-28,972
-58% -$2.58M 0.1% 197
2022
Q2 		$4.14M Sell
50,003
-9,467
-16% -$754K 0.2% 103
2022
Q1 		$4.58M Sell
59,470
-2,053
-3% -$172K 0.18% 109
2021
Q4 		$5.44M Sell
61,523
-6,502
-10% -$537K 0.19% 102
2021
Q3 		$5.26M Sell
68,025
-4,466
-6% -$352K 0.19% 93
2021
Q2 		$6.05M Sell
72,491
-14
-0% -$1.11K 0.22% 85
2021
Q1 		$5.47M Sell
72,505
-3,243
-4% -$265K 0.18% 105
2020
Q4 		$6.64M Sell
75,748
-5,125
-6% -$406K 0.23% 81
2020
Q3 		$6.15M Buy
80,873
+9,991
+14% +$1.01M 0.25% 83
2020
Q2 		$8.74M Sell
70,882
-1,056
-1% -$105K 0.38% 70
2020
Q1 		$6.08M Sell
71,938
-491
-0.7% -$42.3K 0.34% 85
2019
Q4 		$6.12M Buy
72,429
+6,763
+10% +$511K 0.21% 118
2019
Q3 		$4.43M Sell
65,666
-685
-1% -$52.8K 0.16% 122
2019
Q2 		$5.68M Sell
66,351
-12,366
-16% -$1.06M 0.19% 125
2019
Q1 		$6.99M Buy
78,717
+9,637
+14% +$893K 0.23% 120
2018
Q4 		$5.88M Buy
69,080
+16,609
+32% +$1.58M 0.21% 116
2018
Q3 		$5.09M Buy
52,471
+1,197
+2% +$119K 0.18% 117
2018
Q2 		$4.83M Buy
51,274
+8,913
+21% +$781K 0.18% 124
2018
Q1 		$3.43M Buy
42,361
+1,285
+3% +$110K 0.13% 121
2017
Q4 		$3.66M Buy
41,076
+32,371
+372% +$2.81M 0.14% 119
2017
Q3 		$810K Sell
8,705
-1,065
-11% -$94.1K 0.04% 249
2017
Q2 		$887K Buy
9,770
+929
+11% +$84.5K 0.04% 247
2017
Q1 		$776K Buy
8,841
+253
+3% +$22.5K 0.04% 254
2016
Q4 		$711K Buy
+8,588
New +$739K 0.04% 254
2016
Q1 		– Sell
-2,045
Closed -$214K – 297
2015
Q4 		$214K Buy
+2,045
New +$214K 0.01% 293

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rice Hall James & Associates's BMRN Position: Q1 2026 in Review

Rice Hall James & Associates increased its BioMarin Pharmaceuticals (BMRN) stake by 4.5% in Q1 2026, buying an estimated $262K and bringing the position to 104,659 shares worth $5.91M. The position accounts for 0.33% of the portfolio, ranked #73.

Rice Hall James & Associates first reported a position in BMRN in Q4 2015 and has held it in 39 quarters since. The position peaked at $8.74M in Q2 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Rice Hall James & Associates held 104,659 shares of BioMarin Pharmaceuticals worth $5.91M as of Q1 2026.
  • Rice Hall James & Associates bought 4,489 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $262K.
  • BioMarin Pharmaceuticals made up 0.33% of Rice Hall James & Associates's portfolio in Q1 2026, its #73 holding.
  • Rice Hall James & Associates first reported a position in BioMarin Pharmaceuticals in Q4 2015 and has held it in 39 quarters since.
  • Rice Hall James & Associates's BioMarin Pharmaceuticals position peaked at $8.74M in Q2 2020.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.